Molecular Diagnostics System and BRAF Mutation Test Launched
Oct 29 2014 Read 1070 Times
Biocartis have announced that it has officially launched its flagship molecular diagnostics system Idylla™. Idylla™’s unrivalled ease of use, access on-demand design, speed and superior sensitivity are unprecedented in the field of molecular diagnostics. Together with Idylla™, Biocartis also released its first oncology assay, the Idylla™ BRAF Mutation Test. Both Idylla™ and the Idylla™ BRAF Mutation Test have obtained CE-IVD marking.
“Molecular testing plays a key role in the treatment decision process. It allows doctors to select specifically designed therapies based on the genetic profile of their patient”, said Rudi Pauwels, CEO and Executive Chairman of Biocartis. “Traditionally, molecular diagnostics involves a series of specialised, labour-intensive and time-consuming steps. As a result, most labs do not perform these tests in-house, but send them to specialised labs where they are batched, often delaying treatment decisions.”
Idylla™, Biocartis’ fully automated, real-time PCR system, sets the standard for a novel way of molecular testing. Idylla™’s access on-demand design allows clinicians to initiate a new test at any given time, without the need for batching or for trained operators. The system’s short turnaround time, between 35 and 120 minutes, enables laboratories to report same-day results, significantly speeding up the treatment decision process. Furthermore, Idylla™’s multiplex capability offers the possibility to detect up to 30 molecular targets simultaneously in the same sample, making the system very well suited for more complex assays.
The BRAF Mutation Test is Idylla™’s first oncology test and is designed to determine the most appropriate treatment for a specific type of skin cancer. The assay can detect mutations directly from FFPE tissue slices in about 90 minutes. This direct processing of FPE tissue slices is unique for BRAF testing. The excellent analytical sensitivity of the Idylla™ BRAF Mutation Test was demonstrated during clinical performance studies.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Editon Articles - More than One Way to Hit the Bullseye - Gas Chromatography - Vacuum Ultraviolet Spectroscopy - News Bites from the UK Laboratory Industry Mass Spectrometry & Sp...
View all digital editions
Jun 26 2019 Basel, Switzerland
Jul 01 2019 Manchester, UK
Jul 03 2019 Tokyo, Japan
Jul 07 2019 Baltimore, MD, USA
Jul 09 2019 Johannesburg, South Africa